Literature DB >> 15264771

Deep brain stimulation in the treatment of dyskinesia and dystonia.

Hiroki Toda1, Clement Hamani, Andres Lozano.   

Abstract

Deep brain stimulation (DBS) has become a mainstay of treatment for patients with movement disorders. This modality is directed at modulating pathological activity within basal ganglia output structures by stimulating some of their nuclei, such as the subthalamic nucleus (STN) and the globus pallidus internus (GPi), without making permanent lesions. With the accumulation of experience, indications for the use of DBS have become clearer and the effectiveness and limitations of this form of therapy in different clinical conditions have been better appreciated. In this review the authors discuss the efficacy of DBS in the treatment of dystonia and levodopa-induced dyskinesias. The use of DBS of the STN and GPi is very effective for the treatment of movement disorders induced by levodopa. The relative benefits of using the GPi as opposed to the STN as a target are still being investigated. Bilateral GPi stimulation is gaining importance in the therapeutic armamentarium for the treatment of dystonia. The DYT1 forms of generalized dystonia and cervical dystonias respond to DBS better than secondary dystonia does. Discrimination between the diverse forms of dystonia and a better understanding of the pathophysiological features of this condition will serve as a platform for improved outcomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15264771     DOI: 10.3171/foc.2004.17.1.2

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  9 in total

1.  Effects of motor imagery training after chronic, complete spinal cord injury.

Authors:  Steven C Cramer; Elizabeth L R Orr; Michael J Cohen; Michael G Lacourse
Journal:  Exp Brain Res       Date:  2006-08-31       Impact factor: 1.972

Review 2.  Understanding the anatomy of dystonia: determinants of penetrance and phenotype.

Authors:  Renata P Lerner; Martin Niethammer; David Eidelberg
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

3.  Decreased dopamine receptor 1 activity and impaired motor-skill transfer in Dyt1 ΔGAG heterozygous knock-in mice.

Authors:  Fumiaki Yokoi; Mai T Dang; Jun Liu; Jason R Gandre; Kelly Kwon; Robert Yuen; Yuqing Li
Journal:  Behav Brain Res       Date:  2014-11-29       Impact factor: 3.332

4.  Selective and sustained α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation in cerebellum induces dystonia in mice.

Authors:  Xueliang Fan; Keryn E Hughes; H A Jinnah; Ellen J Hess
Journal:  J Pharmacol Exp Ther       Date:  2011-12-14       Impact factor: 4.030

Review 5.  Animal models for dystonia.

Authors:  Bethany K Wilson; Ellen J Hess
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

6.  Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells.

Authors:  Jeffrey W Hewett; Bakhos Tannous; Brian P Niland; Flavia C Nery; Juan Zeng; Yuqing Li; Xandra O Breakefield
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-11       Impact factor: 11.205

7.  Deep brain stimulation improves quality of life in pantothenate kinase-associated neurodegeneration.

Authors:  Kiran P Sathe; Anaita U Hegde; Paresh K Doshi
Journal:  J Pediatr Neurosci       Date:  2013-01

8.  Pregnancy and Delivery in a Generalized Dystonia Patient Treated with Internal Globus Pallidal Deep Brain Stimulation: a Case Report.

Authors:  Hye Ran Park; Jae Meen Lee; Hyeyoung Park; Chae Won Shin; Han Joon Kim; Hee Pyoung Park; Dong Gyu Kim; Beom Seok Jeon; Sun Ha Paek
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153

9.  Long-Term Clinical Outcome of Internal Globus Pallidus Deep Brain Stimulation for Dystonia.

Authors:  Hye Ran Park; Jae Meen Lee; Gwanhee Ehm; Hui-Jun Yang; In Ho Song; Yong Hoon Lim; Mi-Ryoung Kim; Keyoung Ran Kim; Woong-Woo Lee; Young Eun Kim; Jae Ha Hwang; Chae Won Shin; Hyeyoung Park; Jin Wook Kim; Han-Joon Kim; Cheolyoung Kim; Dong Gyu Kim; Beom Seok Jeon; Sun Ha Paek
Journal:  PLoS One       Date:  2016-01-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.